您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Spebrutinib
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Spebrutinib
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Spebrutinib图片
CAS NO:1202757-89-8
包装与价格:
包装价格(元)
5 mg电议
10 mg电议
50 mg电议
100 mg电议
1 mL*10 mM(in DMSO)电议

产品名称
AVL-292
CC-292
LMK-435
产品介绍
Spebrutinib 是一种共价的、高效的、选择性的、具有口服活性的BTK抑制剂 (IC50:0.5 nM)。

产品描述

Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.

体外活性

口服3-30 mg/kg AVL-292抑制胶原蛋白诱导的小鼠关节炎模型中的炎症临床症状,包括关节和爪肿胀以及感染爪的可见发红的减少.

体内活性

AVL-292通过抑制BTK的活性,进一步抑制B细胞的增殖,EC50为3 nM。AVL-29对在Ramos细胞中的BTK产生抑制作用,EC50为8 nM,具有剂量依赖性,并且抑制了下游的BCR通路。

激酶实验

Procedures for BTK OMNIA Assay: The Omnia continuous read assay is performed essentially as described by the vendor. The assay conditions are: 40 μM ATP (1X KMATP), 10 μM Y5-Sox, and 10 nM BTK enzyme. Briefly, a substrate mix containing 1.13X ATP and the Y5 Sox substrate is first prepared in 1X Omnia Kinase Reaction Buffer (KRB) consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM?β-glycerophosphate, 5% glycerol, and 0.2 mM DTT. For IC50 measurements, 5 μL of enzyme are incubated with serially diluted (3-fold) compounds prepared in 50% DMSO in a Corning (#3574) 384-well, white, non-binding surface microtiter plate at 25°C for 30 min. Kinase reactions are started with the addition of 45 μL of the ATP/Y5 substrate mix and monitored at λex360/λem485 in a Synergy 4 plate reader for 60 minutes. Progress curves from each well are examined for linear reaction kinetics and fit statistics. Initial velocity from each reaction is determined from the slope of a plot of relative fluorescence units versus time and then plotted against inhibitor concentration to estimate IC50 using the Response, Variable Slope model in GraphPad Prism from GraphPad Software.

细胞实验

A suspension of resting purified na?ve human B cells isolated by negative selection in RPMI is prepared at 0.4–0.5 × 106 cells/ml. Cells are mixed together with α-human IgM (final concentration of 5 μg/ml in each well) and vehicle (dimethyl sulfoxide) or AVL-292 (final concentrations of 0.01, 0.1, 1.0, 10.0, 100.0, or 1000 nM per well) and seeded in a 96-well plate. Cells are incubated for 56 hours in a humidified incubator maintained at 37°C and 5% CO2. 3H-Thymidine is added (final concentration of 1 μCi in each well) and cells are incubated overnight, harvested, and measured for 3H incorporation. Experiments are performed in triplicate.(Only for Reference)

Cas No.

1202757-89-8

分子式

C22H22FN5O3

分子量

423.44

别名

AVL-292;CC-292;LMK-435

储存和溶解度

H2O:<1 mgml
Ethanol:<1 mgml
DMSO:79 mg/mL (186.6 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years